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Abstract
Background Anovel acoustic coupling fluid (ACF),with the potential to reduce surgically induced image artefacts during intraoperative
ultrasound imaging in brain tumour surgery, has been evaluated with respect to image quality and safety in a clinical phase 1 study.
Methods Fifteen patients with glioblastoma (WHO grade IV) were included. All adverse events were registered in a 6-month
study period. During acquisition of 3D ultrasound image volumes, three different concentrations of the ACF and Ringer’s
solution were filled into the resection cavity. The effect of ACF on the ultrasound images was rated by the operating surgeon,
and by five independent neurosurgeons evaluating a pair of blinded images from all patients. Images from all patients were
analysed by comparing pixel brightness in a noise-affected region and a reference region.
Results The operating surgeon deemed the ACF images to have less noise than images obtained with Ringers’s solution. The
blinded evaluations by the independent neurosurgeons were significantly in favour of ACF (p < 0.0001). The analyses of pixel
intensities showed that the ACF images had lower amount of noise than images obtained with Ringer’s solution. No radiological
sign of inflammation nor circulatory changes was found in the early postoperative MR images. Of the nine complications
registered as serious events in the study period, none was deemed to be caused by the ACF.
Conclusion The ultrasound (US) images obtained using ACF have significantly less noise than US images obtained with
Ringer’s solution. The rate of adverse events was comparable to what has been reported for similar groups of patients.
Keywords Ultrasound artefacts . Ultrasound image quality . Acoustic coupling fluid (ACF) . Artefact reduction
Introduction
Prognosis in patients with primary brain tumours depends on
histological classification where glioblastoma patients have a
median survival reported from 9 to 17 months [14, 16]. Tools
for enhancing surgical resection of brain tumours, in particular
gliomas, are increasing [12, 13, 17, 19]. There seems to be an
agreement that achieving extensive resections, when done
safelywithout jeopardising neurological function, is important
since it improves survival both for high-grade and low-grade
gliomas [6, 12, 15].
Ultrasound is currently used as a tool for providing intra-
operative 2D or 3D images for the purpose of tumour locali-
zation and resection control. For the use in resection control,
the resection cavity is filled with saline or Ringer’s solution to
provide acoustic coupling between the ultrasound transducer
and tissue. However, attenuation of acoustic waves is very low
in water-based irrigation fluids (saline, Ringer’s solution)
compared to the brain. This difference in attenuation is the
cause of artefacts that may severely degrade the ultrasound
images. These artefacts are seen as high-intensity signals at
the resection cavity wall and beyond, potentially masking a
small tumour remnant and generally make the image interpre-
tation more difficult [11].
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The cross-disciplinary research group in the Norwegian
National Advisory Unit for Ultrasound and Image-guided
Therapy at St. Olavs Hospital Trondheim, Norway, has devel-
oped a fluid (ACF) intended for use in the resection cavity
during ultrasound imaging. The purpose of the acoustic fluid
is to reduce noise in the ultrasound images, and thereby pro-
vide images with better ultrasound image quality, which may
provide a better basis for clinical decision making and make it
easier to detect small tumour remnants near the end of an
operation.
The ACF’s effect on image quality was first tested in lab-
oratory measurements using phantoms or fresh animal ca-
davers. Safety has previously been assessed through two ani-
mal studies [2]. In the first pre-clinical study, we injected the
acoustic fluid subcortically in eight rats. The rat brains were
harvested 9 days later, and there were normal histopathologi-
cal findings including immunohistochemistry. In a second
preclinical study with six pigs, we injected the fluid in the
cerebrospinal fluid circulation. After 13–16 days, tissue sam-
pling of dura and brain parenchyma both above and below the
tentorium was performed. Microscopic analysis and immuno-
histochemistry did not reveal any sign of inflammation or
acute cellular response, neither inmeninges, nor in brain tissue
or vessels. Furthermore, no gliosis nor microglial response
was observed. There were no signs of seizure or seizure ac-
tivity on EEG, and in addition, there were no clinical suspi-
cion of altered neurological function.
A clinical phase I study was thereafter designed, approved
and performed to assess safety and efficacy of the new acous-
tic coupling fluid in surgery of 15 patients with glioblastoma.
This paper summarises the results obtained regarding the ef-
fect of the fluid on image quality, and the preliminary assess-
ment of patient safety. The main objective of the image anal-
ysis was to compare the image quality obtained using three
different concentrations of the novel acoustic coupling fluid
with the image quality obtained using Ringer’s solution. The
patient safety was assessed by clinical variables recorded prior
to and during the intervention, as well as in postoperative
controls within 24–72 h, 1 month and 6 months.
Methods and material
Study design and objectives
The clinical study is a single-centre prospective study, per-
formed at the department of Neurosurgery, St. Olav
University Hospital, Trondheim, Norway. The study was ap-
proved by the regional ethical committee (REC Central, ap-
proval 2012/1266) and Norwegian Medicines Agency
(EudraCT No. 2012-005567-27). Informed consent was ob-
tained from all individual participants included in the study.
Sponsor of the study was the Norwegian National
Advisory Unit for Ultrasound and Image-guided Therapy
(USIGT) at St. Olav University Hospital.
The objective of the clinical study was to test the fluid
during surgery for histopathologically proven glioblastoma
to assess safety and efficacy on image quality. The study
was not designed to test the effect on the extent of the
resection.
Study population and baseline characteristics
The study aimed to include 15 patients, male and female >
18 years undergoing resection for glioblastoma. The exclusion
criteria included hypersensitivity to egg protein, peanut pro-
tein, soy protein, glycerol and allergies to diary and marine
products.
The first patient was included in October 2013, while the
last examination of the last patient included in the study was
performed on May 3, 2016. A total of 18 patients gave their
consent to be included in the clinical study. In three patients,
the biopsies taken early in the surgery did not confirm a his-
topathology of glioblastoma. These three patients were there-
fore not included in accordance with the study protocol, and
the ACF was not used during surgery.
In Table 1 the patient demographics and preoperative status
is shown. The patients enrolled in the study had a male dom-
ination and a high percentage of tumours located in the
left brain hemisphere (73%).
Fluids and equipment
The ACF is a sterile mixture consisting of glycerol, vegetable
oil, emulsifier and sodium chloride. The testing of the novel
ACF involved 3 different dilution of the acoustic attenuating
components; ACF-1, ACF-2 and ACF-3. The three different
concentrations of ACF was produced by the hospital pharma-
cy (Sykehusapoteket, St. Olavs Hospital, Trondheim) on the
day of surgery.
The ultrasound data were obtained at different stages
(two or three) of the surgery, using Ringer’s solution and
ACF. The ultrasound acquisition was obtained with the
SonoWand Invite system (Sonowand AS, Trondheim,
Norway), using a flat linear probe (12 FLA) with frequency
range 6–12 MHz. The SonoWand Invite system combines
ultrasound imaging with neuronavigation technology, en-
abling acquisition of 3D ultrasound image volumes during
surgery [19]. Navigated intraoperative ultrasound data may
be presented as overlays on the preoperative MR data, side-
by-side or as 3D US volumes alone. The surgeon is able to
navigate seamlessly in 3D US volume. The rapid and flex-
ible image acquisition makes it possible to make repeated
ultrasound acquisitions during an operation.
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Administration of the fluids
After partial removal of the tumour, the fluids were filled into
the resection cavity just prior to ultrasound image acquisition
using a 50 ml syringe. After the 3D US acquisitions, the re-
spective fluid was removed using a suction device. The ACF
has a white colour. After each ultrasound acquisition with
ACF, the fluid was sucked out and the cavity was flushed with
Ringer’s solution until there was no discolouration of the
Ringer. A laboratory dilution test showed that even by a dilu-
tion with water to 0.25% ACF, a considerable discolouration
was still observed. Flushing until no discolouration is seen
should ensure close to complete removal of ACF after US
imaging.
Safety - clinical variables
Safety was assessed by registration of adverse events and by
dedicated clinical tests and postoperative MR imaging. Any
serious adverse events that occurred throughout the study was
reported to the legal authorities (Statens Legemiddelverk) ac-
cording to ICH/GCP-guidelines.
Research nurses involved in the study were collecting clin-
ical data from the patients, both through clinical examinations
and from electronic medical records by using validated out-
come measures. In addition, included patients were scheduled
for controls as outpatients to both the principal investigator/
surgeon (GU) and a research nurse at 1 and 6 months. MRI-
images were controlled and assessed by an experienced neuro
radiologist. The core patient safety parameters investigated in
the study were inflammations of the brain tissue, development
of hydrocephalus and epileptic seizures. All detectable ad-
verse events, both during operation as well as events that were
registered in the medical journal in the postoperative period,
were registered by the research nurses. Serious adverse events
(SAEs) and suspected unexpected serious adverse reaction
(SUSARs) were reported to the legal authorities (Statens
Legemiddelverk).
Clinical variables acquired pre- and postoperatively (1–
3 days prior to surgery; 24–72 h, 30 days and 6 months post-
operatively) included Karnofsky performance status,
Charlson comorbidity index, Glasgow Coma Scale, Mini
Mental Status and NIH Stroke scale. Patient-reported quality
of life (EQ-5D 3L) was acquired by self-registration before
surgery and telephone controls (at 1 and 6 months). MR T1-
weighted images were obtained prior to surgery (1–3 days),
early postoperative (24–72 h after surgery), at 1 month and at
6 months. Diffusion-weighted images were acquired early
postoperatively in all patients. The postoperative MR images
were evaluated with respect to any indications of inflamma-
tion in the brain or meningitis, significant circulatory changes
or hydrocephalus.
Image evaluation and analyses
The qualitative assessment of the ultrasound images obtained
by using the different fluids in the resection cavity was done
both in the operating room by the operating surgeon and post-
operatively by five independent neurosurgeons.
In the operating room, the ultrasound images acquired
using the different fluids in the resection cavity were displayed
on the SonoWand system for visual inspection. Each of the
Table 1 Patient demographics and preoperative clinical status




Preoperative symptoms*, n (%)
Headache 4 (27)
Seizures 5 (33)
Cognitive symptoms 5 (33)
Unsteadiness/ataxia 5 (33)
Visual disturbances 1 (7)
Aphasia/dysphasia 7 (47)
Cranial nerve deficits 2 (13)
Motor deficits 2 (13)
NIH Stroke Scale ≥ 2, n (%) 2 (13)
Mini Mental Status ≤ 28, n (%) 7 (47)
Karnofsky Performance Status ≥ 70, n (%) 14 (93)
American Society of Anaesthesiology score (ASA score), n (%)
1–2 12 (80)
≥ 3 3 (20)






Insula/basal ganglia 2 (13)
MRI findings
Contrast enhancement/ring on MRI, n (%) 15 (100)
Tumour crossing midline, n (%) 2 (13)
Growth into ventricular system, n (%) 5 (33)
Eloquent location (Sawaya grade 3), n (%) 9 (60)
Left-sided tumour, n (%) 11 (73)
Preoperative tumour volume, cm3, mean ± SD 35 ± 25
Max depth from craniotomy, mm, median ± IQR** 55 ± 17
Largest diameter oedema, mm, median ± IQR** 70 ± 26
Midline shift, mm, median ± IQR** 3 ± 4
Primary operation, n (%) 14 (93)
*Multiple symptoms/locations can be present for a patient
** Interquartile range
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image volumes was individually rated with respect to the de-
gree of image artefacts according to a three-level grading
(none – some – much). In addition, the surgeon rated which
of the image volumes acquired with the different fluids that
provided the overall best image quality with respect to delin-
eation of anatomy and level of noise.
The postoperative assessment of the ultrasound images was
performed in a blinded fashion by five consultant neurosur-
geons. One image obtained with Ringer’s solution and one
image obtained with ACF in the resection cavity was present-
ed in arbitrary order from each patient and rated using a 10-
point scale (1 = least, 10 = best). The two images were obtain-
ed consecutively with only a few minutes interval. The five
observers rated the images by answering the three questions:
1. How easy is it to see the difference between tumour tissue
and its surrounding brain tissue in the ultrasound image?
(provided that the tumour is not completely resected)
2. How easy is it to interpret the image in the region below
the resection cavity in the ultrasound image?
(provided a resection cavity is present)
3. How easy is it to use the image to identify remaining
tumour tissue (for resection)?
The quantitative image analyses were performed postoper-
atively by a single operator blinded for the results of the qual-
itative image analyses using the software 3DSlicer 4.4.0 and
Matlab 9.0.0 (MathWorks).
Two different regions of interests (ROI) were selected
for analyses in each of the acquired image volumes. One
region (30 × 10 × 10 mm) was selected below the resec-
tion cavity in the image volume, while the other region
(5 × 5 × 5 mm) was selected at similar depth but lateral for
the resection cavity and served as a reference region for
the expected intensities in the ultrasound image volume as
shown in Fig. 1. The operator strived to obtain a reference
region in tissue that were expected to be similar as the
tissue below the resection cavity, as deemed from the
preoperative MR T1 images. That is, if the tissue below
the resection cavity was oedematous, the reference region
was preferably selected in oedematous tissue and at the
same depth, if possible. The median brightness of the
pixels in the respectively ROIs was calculated. The fluid
providing a median intensity of the ROI #1 being closest
to the median intensity of the reference ROI #2, was
interpreted to be the fluid providing the most correct rep-
resentation of tissue in the ultrasound images.
Statistical methods
SPSS Statistics was used for descriptive data analyses. QQ-
plots were used to test for normal distribution. Mean ± SD are
presented if data is normally distributed while medians and
interquartile range (IQR) are presented if data are skewed.
Kaplan-Meier was used for survival curve. Independent sam-
ples t-test was used for the quantitative image evaluations,
comparing the difference in intensity of the two selected
ROIs in the images acquired with different fluids in the resec-
tion cavity. The Pearson’s chi-squared test was used for eval-
uation of differences in rating of the images by the surgeon in
the operating room.
The postoperative qualitative image evaluation involving
five raters and three questions was analysed by using a repeat-
ed measures ANOVA (analysis of variance) statistical model.
Results
Ultrasound images with Ringer or ACF in the resection cavity
could be successfully obtained from all the included 15 glio-
blastoma patients and both qualitative and quantitative assess-
ment of the images were performed.
Qualitative assessment of the fluids’ impact on image
quality
The ultrasound data acquired with different fluids was
displayed on the Sonowand Invite system for qualitative in-
terpretation by the operating surgeon. The 3D image volumes
Fig. 1 Image slice extracted from a 3D US volume, with the two regions
of interest (ROIs) selected for analysis of median intensities. The smaller
square indicates the reference region (#2), in which similar tissue as
below the resection cavity is expected. The larger rectangle (#1) is select-
ed to be directly below the resection cavity, in an area where enhancement
artefacts are expected to be present
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were typically displayed as two image slices for each volume
as shown in Fig. 2. A navigation pointer was used to inspect
the image volumes on the navigation display, with the image
slices being extracted on basis of the position and orientation
of the navigation pointer.
Intraoperative assessment by the operating
neurosurgeon
The operating neurosurgeon (GU) assessed the ultrasound im-
ages obtained with Ringer’s solution in the resection cavity to
contain more image artefacts than images obtained with any of
the variants of ACF. The chi-square test showed a significant-
ly higher noise level in the Ringer images compared to the
ACF images (p < 0.05).
The operating surgeons were also asked to choose the im-
age with the best image quality.
The ACF-2 had the highest success rate (# wins), as it
was rated to have the best image quality in 19 of 29 test
sequences (65.5%). There was no significant difference in
the # wins between the three concentrations of ACF.
Ringer’s solution had equal quality with the ACF in 1
of 31 test rounds (3.2%).
Postoperative blinded rating by independent
neurosurgeons
A pair of images with Ringer’s solution and ACF in random
order from each of the 15 operations was evaluated by five
independent neurosurgeons. The neurosurgeons were asked to
answer three questions for each pair. Table 2 lists the evalua-
tions for all three questions across the 15 image pairs and the
five raters. The results were significantly in favour of ACF
(p < 0.0001). For question 3, BHow easy is it to use the image
to identify remaining tumour tissue (for resection)?^ the mean
difference ACF–Ringer’s was 3.03 (2.39, 3.66). The differ-
ence between ACF and Ringer’s solution was significant
(p < 0.00001) for all five raters.
As seen in Table 2, there is some heterogeneity in the
judgement of image quality (ACF–Ringer) across the 15 im-
ages, with no improvement seen in the images from patient 3,
and a non-statistically significant difference (p = 0.10) of less
than 1 unit seen in the images from patient 10. For the other 13
patients, the differences between ACF and Ringer are all sta-
tistically significant, with values ranging between 1.60 and
5.20.
Examples of the ultrasound images that were evaluated for
patient 2, 6 and 13 are shown in Figs. 3, 4 and 5.
Fig. 2 Display from the navigation system, showing two perpendicular
image slices extracted from the MRI or 3D ultrasound volume according
to the orientation of the navigated tool. The preoperative MR T1-
weighted contrast image is shown to the left. The middle column shows
the ultrasound images acquired with Ringer’s solution in the resection
cavity, and in the right column, the ultrasound obtained with ACF-3 is
shown overlaid the MR images
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For the two patients where the neurosurgeons found no
difference between ACF and Ringer’s solution the cavities
were very narrow, causing the sound waves to mostly go
through normal brain tissue as seen in Fig. 6 of patient 3.
Quantitative image analyses
The median voxel intensity in a region below the resection
cavity (ROI #1) and a reference region (ROI #2) laterally to
the resection cavity was calculated for each of the ultrasound
image volumes. In Fig. 7, the difference in the median values
between ROI #1 and ROI #2 is plotted. The fluid ACF-2 is
having the lowest average difference in intensity between the
selected regions of interests for the ACF fluids, while Ringer’s
solution has the highest average difference. A lower difference
indicates an intensity level below the resection cavity being
more similar to the intensity level of the reference region,
whereas a higher and positive difference in pixel brightness
level will indicate an artificial signal enhancement in the re-
gion below the resection cavity.
All series of differences ROI #1–ROI #2 for each fluid
were normally distributed (Kolmogorov-Smirnov, p > 0.2),
and consequently t test (one-sample) was used for the statisti-
cal analyses. The statistical analyses show that the images
obtained with Ringer’s solution, ACF-1 and ACF-3 have dif-
ferences significantly greater than zero (p < 0.01). For images
obtained with ACF-2, the null hypothesis of zero difference
cannot be rejected (p > 0.1).
Table 2 Score of ACF vs.
Ringer’s solution for the 15








Difference ACF - Ringer (95% CI) p value
1 2.80 (1.37) 8.00 (0.53) 5.20 (4.42, 5.98) < 0.0001
2 3.73 (1.71) 7.73 (0.70) 4.00 (3.02, 4.83) < 0.0001
3 3.40 (2.10) 3.40 (2.29) 0.00 (− 1.64, 1.64) 1.00
4 2.60 (1.64) 7.07 (0.96) 4.47 (3.46, 5.47) < 0.0001
5 4.87 (1.81) 7.33 (0.72) 2.47 (1.43, 3.50) < 0.0001
6 4.60 (1.59) 7.20 (1.74) 2.60 (1.35, 3.85) 0.0002
7 5.33 (2.32) 6.93 (1.28) 1.60 (0.20, 3.00) 0.0267
8 3.73 (1.94) 6.53 (1.92) 2.80 (1.35, 4.25) 0.0005
9 4.67 (1.88) 6.87 (1.13) 2.20 (1.04, 3.36) 0.0006
10 6.27 (1.71) 7.20 (1.26) 0.93 (− 0.19, 2.06) 0.10
11 5.20 (2.08) 7.22 (0.82) 2.13 (0.96, 3.31) 0.0009
12 4.00 (2.07) 7.87 (0.92) 3.87 (2.67, 5.06) < 0.0001
13 4.80 (1.97) 7.80 (0.68) 3.00 (1.90, 4.10) < 0.0001
14 3.20 (2.40) 7.20 (1.15) 4.00 (2.59, 5.41) < 0.0001
15 4.00 (2.04) 9.00 (0.85) 5.00 (3.83, 6.17) < 0.0001
a b
Fig. 3 (patient 2). Image a is with Ringer’s solution in the cavity and image b is with ACF. At the tip of the navigation pointer (green dot), there are
artefacts in a with the same intensity as remaining tumour tissue, which is absent in b
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Postoperative adverse events and clinical follow-up
The postoperative adverse events were found by inspection of
patient journals, discharge reports, MR imaging and interviews
with the patients. A few patients refused or were too exhausted
to participate in some of the scheduled controls, interviews and/
or MRI investigations during the 6-month study period.
Accordingly, follow-up data are missing in these patients.
Early postoperative (24–72 h) MR images did not indicate
any inflammation or adverse effect in the brain tissue, nor any
significant circulatory changes or dilated ventricles in any of
the 15 patients included in the study. Neither did the MR
examination performed in 13 patients 1 month after the oper-
ation indicate any inflammation of tissue or dilated ventricles.
In 12 patients having an MR examination at 6 months
postoperatively, one of the patients was measured to have
dilated ventricles. None of the patients had any indication of
inflammation of tissue. Tumour recurrence was found in 5 of
12 patients (42%) at the 6-month follow-up.
In Table 3, there is an overview of the adverse events found
by the postoperative controls and by examination of digital
patient journals. One patient had fever (38.6 °C) and neck
stiffness occurring 6 days after the surgery, along with a
CSF leakage causing subcutaneous accumulation. Samples
from the subcutaneous CSF were acquired along with samples
obtained by lumbar puncture. The CSF samples did not imply
any bacterial growth. The CSF of the lumbar samples
contained erythrocytes. The CRP was normal.
Two patients were reported to have seizures within
30 days after surgery. One patient had an epileptic seizure
a b
Fig. 4 (patient 6). Image a is with Ringer’s solution and b is with ACF in the operation cavity. The artefact signals in a makes it difficult to do a safe
judgement of tumour borders. In b, the yellow marker in the image is pointing at signals that are interpreted as tumour at the bottom of the cavity
a b
Fig. 5 (patient 13). aWith ACF and b with Ringer’s solution in the operation cavity. In b, it is difficult to interpret the image in the region below the
operation cavity because of artefacts
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within 3 days after surgery. This patient had in the 3 weeks
before the operation had three episodes with sudden apha-
sia lasting only a few seconds and three episodes with
shivering of right hand lasting about 1 min. The patient
was operated in the cingulate gyrus and some tumour
tissue was intentionally left behind. The other patient, that
was operated in the right sensory cortex and close to right
pyramidal tract, had attacks with painful rigidity in the
left leg starting 6 days after surgery. It was interpreted
as a focal seizure. Antiepileptic drugs had very limited
effect. None of the patients were given pre-and postoper-
ative prophylactic antiepileptic drugs. There were two
incidences of epidural hematoma, of which one required
surgical evacuation.
The median survival for the glioblastoma patients enrolled
in the study was 326 days (10.9 months). Figure 8 shows the
survival curve. Three of the 15 glioblastoma patients died
between the 1-month and the 6-month follow-up period.
Health-related quality of life (QoL), cognitive function
and functional status
The patients reported their health-related QoL in the EQ-5D
questionnaire. A minimal clinically important difference
Fig. 7 Differences inmedian grey
level in region below resection
cavity (ROI #1) and reference
tissue region (ROI #2). The
average difference is indicated
with a circle, and error bars
indicate 95% confidence interval
a b
Fig. 6 (patient 3). Image a is with Ringer’s solution and b is with ACF in the operation cavity. Since the cavity is narrow and the sound waves mostly
pass through brain tissue, there is no enhancement artefacts, and the tumour below the cavity is shown in both images
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(MCID) of ± 0.15 was used for defining whether the patient’s
QoL improved or deteriorated [9]. Compared to baseline 5 of
14 patients (36%) had deteriorated at 1 month and 5 of 11
patients (45%) at 6 months after surgery.
Cognitive function of the patients was evaluated using the
mini mental status (MMS) and the cognitive functioning scale
of EORTC QLQ-C30. For the functioning scale of EORTC
QLQ-C30, a MCID of 10 points was used to evaluate im-
provement or deterioration relative to the status prior to sur-
gery [5]. At 1 month after surgery, 11 patients answered the
EORTC QLQ-C30 questionnaire. Four of them reported im-
proved cognitive function (36%), four reported unchanged
cognitive function (36%) and three reported deterioration
(27%).
For the MMS, a drop of ≥ 2 compared to the preoperative
score was registered in 9 of 14 patients immediately after
surgery (24–72 h). At 1 month, three patients had a drop ≥ 2
compared to the preoperative score.
There was no drop in Glasgow Coma Scale neither imme-

















Survival FunctionFig. 8 Cumulative survival curve
for the enrolled glioblastoma
patients
Table 3 Postoperative events of
the included patients Type of postoperative event Within 30 days
No. (%)
Between 1 and 6 months
No. (%)
Fever (unknown origin) 1 (7)* 1 (7)
CSF-leak 1 (7) 0 (0)
Epileptic seizures 2 (13)* 1 (7)
Epidural hematoma requiring surgery 1 (7)* 0 (0)
Epidural hematoma without clinical symptoms 1 (7) 0 (0)
UTI/urinary retention 3 (20) 0 (0)
Salmonella infection 1 (7) 0 (0)
Aloofness (episode of 15 min) 1 (7) -
Subdural effusion 1 (7)* 0 (0)
Pneumonia 2 (13) 1 (7)
Itchy rash 2 (13) 0 (0)
Syncope (3 episodes) 1 (7) 0 (0)
Fungal mouth infection 1 (7) 0 (0)
Cardiac arrhythmia 0 (0) 1 (7)
Chronic subdural hematoma 0 (0) 1 (7)*
Febrile neutropenia 0 (0) 1 (7)
Death 0 (0) 3 (20)*
*Reported as serious adverse events (SAEs) or suspected unexpected serious adverse reaction (SUSARs) accord-
ing to the ICH/GCP-guidelines
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Scale 3 of 14 patients had a change > 2 immediately after the
operation. At 1 month and 6 months after the operation, this
change was registered in one patient.
The functional impairment was evaluated by a drop in KPS
from ≥ 70 before surgery to ≤ 60 after surgery. Immediately
after surgery (24–72 h), such a drop was registered in seven
patients. One month after surgery, the number with such a
drop compared to preoperative value was reduced to three
patients.
Discussion
The study has investigated the safety and image quality of a
novel acoustic coupling fluid (ACF) intended to be used dur-
ing ultrasound imaging in brain tumour surgery. Three con-
centrations of ACF were used in addition to Ringer’s solution,
which served as the current gold standard.
The image quality for each of the ultrasound images ob-
tained was assessed and rated by the surgeon in the operating
room during the ultrasound imaging and in a blinded fashion
postoperatively by five neurosurgeons with experience in ul-
trasound imaging. In addition, the impacts on noise of the
three different ACF concentrations and the Ringer’s solution
were investigated by quantitative analyses of the pixel bright-
ness in defined ROI’s. All the analyses demonstrate that there
is less noise in the group of ultrasound images obtained with
ACF in the resection cavity compared to the images obtained
with Ringer’s solution. The postoperative assessment of the
ultrasound images indicates that the improved image quality
will make it easier to identify remaining tumour in the area
below the resection cavity. The improved ultrasound image
quality with ACF may lead to better clinical decision support
for the surgeons.
When considering the improvement in image quality for
the individual patients, there was none of the cases where
the use of ACF led to poorer image quality compared to
Ringer’s solution. However, in two cases with small resection
cavities, the postoperative analyses indicated a similar image
quality between ACF and Ringer. This is in accordance with
the theoretical background for the artefacts. As long as the
sound waves go through tissue, there will not be enhancement
artefacts. Therefore, the subjective interpretation of the degree
of improvement in image quality will also depend on the size
of the resection cavity.
When comparing the noise level observed in the three dif-
ferent concentrations of ACF, the differences were small com-
pared to the differences between ACF and Ringer’s solution.
The attenuation of the fluid is a balance between being too low
(compared to attenuation in brain tissue) and thereby not re-
ducing the noise as much as it could have done and being too
highwhich could lead to shadowing artefacts in the ultrasound
image below the resection cavity. For that reason, fluid with
three different concentrations of the sound attenuating com-
ponent was tested. The quantitative analyses of image contrast
show that the ACF-2 images are most similar to the intensity
of a reference region with similar tissue. The surgeon’s peri-
operative assessment of the different images acquired with
ACF in the cavity also favours the same concentration
(ACF-2).
There were three deaths within the 6-month study period.
Two of the patients died approx. 5.5 months after surgery, with
recurrent tumour apparent on the MRI obtained 1 month after
surgery. The deaths were caused by tumour progression. One
patient died 5 months after surgery. In this patient, it was not
identified tumour recurrence on the 1-month MRI examina-
tion. The adjuvant treatment with radiation therapy and che-
motherapy was stopped early after it was initiated, due to
neutropenia and deteriorated health. Even if MRI has not ver-
ified tumour growth for this patient, the death of the patient
was considered to be caused by tumour growth and factors
related to the progression of the disease. Both overall survival
and 6-month death rate for patients in this study are compara-
ble to the results reported for a similar group of patients con-
secutively operated at the same hospital from 2011 to 2013
[10].
Postoperative MRI examinations have not revealed any
signs of inflammations nor toxicity in the brain of the patients
included in the study. MRI is known to be sensitive for detec-
tion of inflammation in the brain parenchyma [8]. This indi-
cates that the ACF fluid is well tolerated by the brain paren-
chyma. Nor has it been found any circulatory changes in the
early postoperative MR images.
Patient number 1 was suspected to have meningitis 6 days
after surgery, with headache, fever and some neck stiffness.
The CRP was normal and tests of the cerebrospinal fluid
(CSF) did not show any bacterial growth. This patient was
operated for a very large tumour that invaded the ventricles.
The tumour was radically removed resulting in a large open-
ing from the resection cavity into the ventricles, and some
blood had inevitably entered the ventricle system. There was
blood in the samples of CSF taken days after surgery. The
blood in the ventricle systemmight therefore explain the fever
episode and neck stiffness. It seems less likely that the use of
ACF in the earlier stages of surgery before opening of the
ventricles should have caused the above stated complication.
In the same patient, the radiologist reported enlarged ven-
tricles as well as tumour growth at the 6-month control. The
clinical follow-up did not reveal any clinical symptoms of
hydrocephalus. The increased risk for hydrocephalus by en-
tering the ventricle during tumour surgery is well known. For
example, a paper from Henry Ford Hospital in Detroit report-
ed 11% hydrocephalus in such patients [3].
Rates of postoperative seizures in patients with gliomas
without preoperative seizures vary in the literature from 4 to
40% in the year following resection, with the first
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postoperative seizure generally occurring within the first
month after craniotomy [7]. In a prospective randomised study
of perioperative seizure prophylaxis from MD Anderson
Cancer Center in Houston, the authors found new seizures
during the 30-day postoperative period in 18.6% of 46 glioma
operations (80% were high-grade gliomas) with no benefit of
prophylaxis [20]. In a retrospective study of 184 glioblastoma
patients, new onset epilepsy during the first 30 days after
resection was found in 16% in the group without prophylactic
antiepileptic medication [4]. The two patients registered to
have postoperative seizures in our study are within the level
of what has been reported by others. However, due to the low
number of patients in our study and the large variation in
postoperative seizures in the literature, we cannot exclude
the possibility that ACF can contribute to the generation of
new seizures.
One patient reported itchy rash on the first postoperative
examination at 1 month. The condition was not treated, and
the rash was not reported in the patient’s journal or the nursing
log. Another patient had a rash on back/neck 2 days after
surgery that was reported as a possible urticaria. Some medi-
cation was altered; the patient was given antihistamine
(cetirizin) and the rash went away the same day.
Quality of life, cognitive function and functional
status
The patient reported quality of life with deterioration found in
36% and 45% at 1 month and 6 months respectively after
surgery was similar to the values found in a study of compa-
rable patients operated at the same hospital from 2011 to 2013,
and assessed in the same way [9].
In the early postoperative examination (24–72 h) of MMS,
there was a drop. Postoperative cognitive dysfunction is a
well-known entity [18] that to our knowledge has not been
studied in the immediate postoperative period after brain sur-
gery. It is likely, however, that the operation itself, and also the
certainty of having an incurable tumour, will influence the
ability of the patients to answer questions immediately after
the operation.
The Karnofsky performance index also dropped immedi-
ately after surgery. We did not find results to compare with in
the literature, but it is likely that the scoring immediately after
a brain tumour operation will be influenced by the operation
itself. In a month, the functional activity was regained in most
of the patients.
Patients operated for glioblastoma have a high rate of post-
operative adverse events [1]. This makes it difficult to identify
adverse events related to the intervention. Even though the
adverse events in this study are within the limits of what have
been reported in other publications, indisputable safety data
requires a higher number of patients operated using ACF in
ultrasound-guided surgery.
Conclusion
In a phase I study of glioblastoma patients, a novel acoustic
coupling fluid (ACF) was able to remove artefacts that appear
in ultrasound images towards the end of tumour removal. Our
findings indicate that the improved ultrasound image quality
with ACF may lead to better clinical decision support for the
neurosurgeons.
Adverse events or complications detected in this limited
group of patients are comparable to what has been reported
for similar patients in other publications.
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Comments Intraoperative ultrasound has been used in neurosurgical
procedures for over 40 years now. Improved image quality of modern
ultrasound machines in combination with their integration in navigational
setups allowing to acquire 3-dimensional ultrasound and to display ultra-
sound along preoperative image datasets facilitating image interpretation
has resulted in a renaissance of intraoperative ultrasound usage in tumour
resections. Despite these technical advances, still image artefacts hinder
reliable ultrasound image evaluation. Among these artefacts, a major
challenge is high intensity signal artefacts at the wall of a resection cavity
that impede to judge resection completeness especially in glioma resec-
tions. Unsgård et al. present a phase I study investigating the application
of an acoustic coupling fluid, which seems to greatly reduce these arte-
facts. It will be interesting to see, whether its application will lead to a
more reliable detection of tumour residues at the resection border and thus
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